Centene to redeem remaining USD 568.66 million notes on Oct. 23
Bitget2026/10/08 14:22Centene issued a redemption notice for all remaining USD 568.66 million of its 4.25% Notes due Dec. 15, 2027. Redemption date set for Oct. 23, 2026, eliminating the 2027 Notes from Centene’s outstanding debt. Redemption price set at 100% of principal, with accrued and unpaid interest to, but excluding, Oct. 23, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centene Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001071739-26-000186), on October 08, 2026, and is solely responsible for the information contained therein.
- Centene issued a redemption notice for all remaining USD 568.66 million of its 4.25% Notes due Dec. 15, 2027.
- Redemption date set for Oct. 23, 2026, eliminating the 2027 Notes from Centene’s outstanding debt.
- Redemption price set at 100% of principal, with accrued and unpaid interest to, but excluding, Oct. 23, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
Crypto prices
More
